{"nct_id":"NCT00546793","title":"Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL","status":"COMPLETED","status_verified_date":"2013-03","start_date":"2008-01","start_date_type":null,"primary_completion_date":"2013-03","primary_completion_date_type":"ACTUAL","completion_date":"2013-03","completion_date_type":"ACTUAL","phases":["PHASE1","PHASE2"],"tickers":["GILD"]}